Daily practice use of bortezomib in relapsed/refractory multiple myeloma: Safety/efficacy results of a compassionate use program in Switzerland. Swiss Med Wkly [Internet]. 2007 Jun. 2 [cited 2026 Feb. 1];137(2122):317-22. Available from: https://www.smw.ch/index.php/smw/article/view/736